Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bill seeks guaranteed contraception access

This article was originally published in The Tan Sheet

Executive Summary

Legislation offered May 13 would establish requirements for pharmacies to ensure provision of FDA-approved contraception, including Teva Pharmaceutical's nonprescription Plan B One-Step and generic levonorgestrel. Rep. Carolyn Maloney, D-N.Y., introduced the House version of the Access to Birth Control Act, H.R. 5309, and said the "bill would prevent a pharmacy from standing between a patient and her doctor" by prohibiting refusals to dispense drugs on religious grounds. Introduced in the Senate as S. 3357 by Frank Lautenberg, D-N.J., the bill would require an out-of-stock pharmacy to help consumers obtain contraception via order, referral or transferred prescription. The American Medical Association previously supported legislation compelling pharmacists to provide appropriate birth control access (1"The Tan Sheet" June 27, 2005)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel